Completed PHASE1 INTERVENTIONAL 2-arm NCT00731471

A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV

A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV

Sponsor: Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal

Conditions Tuberculosis

Interventions MVA85A

Updated 5 times since 2017 Last updated: Mar 25, 2011 Started: Aug 31, 2008 Primary completion: Jan 31, 2011 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00731471, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal, it has been updated 5 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal
University of Oxford

Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dakar, Senegal